Sagespring Wealth Partners LLC lifted its position in shares of CVS Health Corporation (NYSE:CVS - Free Report) by 88.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 12,741 shares of the pharmacy operator's stock after acquiring an additional 5,980 shares during the quarter. Sagespring Wealth Partners LLC's holdings in CVS Health were worth $863,000 at the end of the most recent quarter.
Other large investors have also recently added to or reduced their stakes in the company. Hopwood Financial Services Inc. purchased a new position in CVS Health in the fourth quarter valued at about $29,000. McIlrath & Eck LLC increased its stake in CVS Health by 32.6% in the 4th quarter. McIlrath & Eck LLC now owns 707 shares of the pharmacy operator's stock valued at $32,000 after purchasing an additional 174 shares in the last quarter. MV Capital Management Inc. boosted its position in CVS Health by 63.9% during the first quarter. MV Capital Management Inc. now owns 741 shares of the pharmacy operator's stock worth $50,000 after purchasing an additional 289 shares in the last quarter. Financial Perspectives Inc grew its holdings in CVS Health by 137.5% in the fourth quarter. Financial Perspectives Inc now owns 805 shares of the pharmacy operator's stock valued at $36,000 after purchasing an additional 466 shares during the last quarter. Finally, Compass Planning Associates Inc acquired a new position in shares of CVS Health during the 4th quarter worth $37,000. 80.66% of the stock is owned by hedge funds and other institutional investors.
CVS Health Trading Down 0.3%
CVS Health stock traded down $0.19 during trading on Thursday, reaching $66.91. The company had a trading volume of 5,208,935 shares, compared to its average volume of 10,943,569. The company has a debt-to-equity ratio of 0.77, a quick ratio of 0.63 and a current ratio of 0.82. The firm has a market capitalization of $84.64 billion, a price-to-earnings ratio of 15.97, a PEG ratio of 0.96 and a beta of 0.56. CVS Health Corporation has a 12-month low of $43.56 and a 12-month high of $72.51. The stock's 50 day moving average price is $65.02 and its two-hundred day moving average price is $60.30.
CVS Health (NYSE:CVS - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The pharmacy operator reported $2.25 EPS for the quarter, topping analysts' consensus estimates of $1.62 by $0.63. CVS Health had a return on equity of 10.59% and a net margin of 1.39%. The business had revenue of $94.59 billion during the quarter, compared to the consensus estimate of $93.07 billion. During the same period in the prior year, the firm posted $1.31 EPS. The business's revenue for the quarter was up 7.0% on a year-over-year basis. As a group, equities analysts expect that CVS Health Corporation will post 5.89 earnings per share for the current fiscal year.
Insider Transactions at CVS Health
In other CVS Health news, Director Guy P. Sansone bought 1,570 shares of CVS Health stock in a transaction that occurred on Thursday, June 5th. The shares were acquired at an average price of $63.70 per share, for a total transaction of $100,009.00. Following the acquisition, the director now owns 12,007 shares of the company's stock, valued at $764,845.90. The trade was a 15.04% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 1.22% of the company's stock.
Wall Street Analyst Weigh In
A number of equities research analysts recently commented on the stock. Royal Bank Of Canada increased their price objective on shares of CVS Health from $74.00 to $81.00 and gave the company an "outperform" rating in a research note on Monday, May 5th. Robert W. Baird raised their price objective on shares of CVS Health from $51.00 to $71.00 and gave the stock a "neutral" rating in a research note on Tuesday, April 15th. Wells Fargo & Company reaffirmed an "overweight" rating and issued a $84.00 target price (up previously from $76.00) on shares of CVS Health in a research note on Tuesday, May 6th. Truist Financial raised their price target on CVS Health from $82.00 to $84.00 and gave the stock a "buy" rating in a research report on Monday, May 12th. Finally, Cowen restated a "buy" rating on shares of CVS Health in a research report on Monday, May 5th. Two research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $74.75.
View Our Latest Stock Report on CVS Health
CVS Health Profile
(
Free Report)
CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.
Recommended Stories
Before you consider CVS Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.
While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
